Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Quinn, A. Desjardins, J. Weingart, H. Brem, M. Dolan, Shannon Delaney, J. Vredenburgh, J. Rich, A. Friedman, D. Reardon, John Sampson, A. Pegg, R. Moschel, R. Birch, R. McLendon, J. Provenzale, S. Gururangan, Janet Dancey, J. Maxwell, S. Tourt-Uhlig, J. Herndon, D. Bigner, H. Friedman (2000)
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 28
A. Pegg, S. Kanugula, S. Edara, G. Pauly, R. Moschel, K. Goodtzova (1998)
Reaction ofO 6-Benzylguanine-resistant Mutants of Human O 6-Alkylguanine-DNA Alkyltransferase with O 6-Benzylguanine in Oligodeoxyribonucleotides*The Journal of Biological Chemistry, 273
D. Johns, A. Iannotti, A. Sartorelli, J. Bertino (1966)
The relative toxicites of methotrexate and aminopterin.Biochemical pharmacology, 15 5
M. Belanich, Monica Pastor, T. Randall, Denise Guerra, J. Kibitel, L. Alas, Ben Li, M. Citron, P. Wasserman, A. White, H. Eyre, K. Jaeckle, S. Schulman, Dori Rector, M. Prados, S. Coons, W. Shapiro, D. Yarosh (1996)
Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine.Cancer research, 56 4
R. Schilsky, M. Dolan, D. Bertucci, R. Ewesuedo, N. Vogelzang, S. Mani, L. Wilson, M. Ratain (2000)
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 8
HS Friedman, J Pluda, JA Quinn (2000)
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant gliomaJ Clin Oncol, 18
Andrew Rowan (1996)
Guide for the Care and Use of Laboratory AnimalsJournal of Medical Primatology, 8
Stewart Johnson, B. Kamen, D. Bigner, H. Friedman (2007)
O4-benzylfolic acid inactivates O6-alkylguanine-DNA alkyltransferase in brain tumor cell linesCancer Chemotherapy and Pharmacology, 60
M. Nelson, N. Loktionova, A. Pegg, R. Moschel (2004)
2-amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase.Journal of medicinal chemistry, 47 15
M. Dolan, R. Moschel, A. Pegg (1990)
Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.Proceedings of the National Academy of Sciences of the United States of America, 87
K. Rajagopalan, I. Fridovich, P. Handler (1962)
Hepatic aldehyde oxidase. I. Purification and properties.The Journal of biological chemistry, 237
C. McCully, F. Balis, John Bacher, J. Phillips, D. Poplack (1990)
A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid.Laboratory animal science, 40 5
H. Behrsing, M. Furniss, Kristine Robillard, J. Tomaszewski, R. Parchment (2010)
In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell linesCancer Chemotherapy and Pharmacology, 65
K. Warren, A. Aikin, M. Libucha, B. Widemann, E. Fox, R. Packer, F. Balis (2005)
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 30
J. Ross, P. Chaudhuri, M. Ratnam (1994)
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implicationsCancer, 73
B. Cox, K. Opheim, H. Teschemacher, A. Goldstein (1975)
Purification and propertiesLife Sciences, 16
J. Quinn, J. Pluda, M. Dolan, Shannon Delaney, R. Kaplan, J. Rich, A. Friedman, D. Reardon, J. Sampson, O. Colvin, M. Haglund, A. Pegg, R. Moschel, R. McLendon, J. Provenzale, S. Gururangan, S. Tourt-Uhlig, J. Herndon, D. Bigner, H. Friedman (2002)
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 9
S. Berg, S. Gerson, K. Godwin, D. Cole, L. Liu, F. Balis (1995)
Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate.Cancer research, 55 20
A. Pegg (2000)
Repair of O6-alkylguanine by alkyltransferasesMutation Research-reviews in Mutation Research, 462
M. Salazar, M. Ratnam (2007)
The folate receptor: What does it promise in tissue-targeted therapeutics?Cancer and Metastasis Reviews, 26
Concentrations of O 4 BF and the metabolite in CSF exceeded the ED 50 of AGT; however, recently reported lack of receptor specificity and pharmacokinetic data suggesting saturable elimination of both O 4 BF and its metabolite may limit dose-escalation and future clinical development of this agent.
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Jun 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.